Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Intellia Therapeutics Inc’s stock clocked out at $12.06, up 3.79% from its previous closing price of $11.62. In other words, the price has increased by $3.79 from its previous closing price. On the day, 5.14 million shares were traded. NTLA stock price reached its highest trading level at $12.235 during the session, while it also had its lowest trading level at $11.63.
Ratios:
To gain a deeper understanding of NTLA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.19 and its Current Ratio is at 5.19. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.11.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30. JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 20 ’25 when CHASE WILLIAM J bought 100,000 shares for $10.03 per share. The transaction valued at 1,003,000 led to the insider holds 134,693 shares of the business.
Dulac Edward J III sold 7,462 shares of NTLA for $104,617 on Jul 23 ’25. The EVP, Chief Financial Officer now owns 106,062 shares after completing the transaction at $14.02 per share. On Jul 01 ’25, another insider, Clark Eliana, who serves as the EVP, Chief Technical Officer of the company, sold 1,022 shares for $9.82 each. As a result, the insider received 10,036 and left with 95,369 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1294604928 and an Enterprise Value of 937543424. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.49 while its Price-to-Book (P/B) ratio in mrq is 1.78. Its current Enterprise Value per Revenue stands at 17.737 whereas that against EBITDA is -1.868.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.29, which has changed by -0.39183056 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $23.76, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is 5.46%, while the 200-Day Moving Average is calculated to be 15.99%.
Shares Statistics:
It appears that NTLA traded 4.65M shares on average per day over the past three months and 3812910 shares per day over the past ten days. A total of 105.33M shares are outstanding, with a floating share count of 101.11M. Insiders hold about 5.81% of the company’s shares, while institutions hold 87.92% stake in the company. Shares short for NTLA as of 1755216000 were 27729214 with a Short Ratio of 5.96, compared to 1752537600 on 28867302. Therefore, it implies a Short% of Shares Outstanding of 27729214 and a Short% of Float of 29.26.
Earnings Estimates
The current rating of Intellia Therapeutics Inc (NTLA) is the result of assessments by 21.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.97, with high estimates of $0.04 and low estimates of -$1.49.
Analysts are recommending an EPS of between -$2.67 and -$4.74 for the fiscal current year, implying an average EPS of -$4.07. EPS for the following year is -$3.92, with 23.0 analysts recommending between -$2.37 and -$5.02.
Revenue Estimates
A total of 24 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $30.87M, resulting in an average revenue estimate of $62.45M. In the same quarter a year ago, actual revenue was $57.88M
